TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02325687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (Standard-of-Care)
Description: All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (Standard-of-Care)
Description: All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (Standard-of-Care)
Description: All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
Study: NCT04173871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protac Myfit®
Description: A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
Study: NCT01684683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline 0.1 bid
Study: NCT01205906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help for tinnitus
Description: Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior group therapy for tinnitus
Description: Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet discussion forum
Description: Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
Study: NCT01684683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Theophylline)
Description: Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
Study: NCT00971425

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemrix (GSK investigational influenza GSK2340272A vaccine)
Description: 2 doses intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemrix (GSK investigational influenza GSK2340272A vaccine)
Description: 2 doses intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: 1 dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: 1 dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose intramuscular injection
Study: NCT03379480

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga arm
Description: Yoga module developed for patients with Schizophrenia
Study: NCT03573440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindful education on eating
Description: Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
Study: NCT04101448

Intervention type: OTHER
Intervention: prevalence
Description: percentage of bronchectasis in COPD and its effect as prognostic measure

Intervention type: OTHER
Intervention: prevalence
Description: percentage of bronchectasis in COPD and its effect as prognostic measure
Study: NCT01297712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Latest generation colonoscopy as diagnostic instrument
Description: this endoscope is used as compared to an older generations cope (classic line) currently in use
Study: NCT00686933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take up to 80 mg daily for 24 months
Study: NCT02383498

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301 Vaccine (Yeast- Brachyury)
Description: GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
Study: NCT01207388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion
Study: NCT00187889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo or sugar pill
Description: Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
Study: NCT06118164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pursing- lip breathing combined with aerobic walking exercise
Description: pursing- lip breathing combined with aerobic walking exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pursing- lip breathing
Description: pursing- lip breathing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic walking exercise
Description: aerobic walking exercise
Study: NCT03278652

Intervention type: OTHER
Intervention: Consumption of drugs for analgesic use
Description: * Regular assessment of pain~* Drug data will be collected (name, dosage, route of administration, time of delivery)
Study: NCT03703687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude intervention
Description: The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence.
Study: NCT03661450

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Decision-Support System
Description: Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
Study: NCT00727948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg tablets, once daily for 45 days
Study: NCT02808949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
Study: NCT01703884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASAQ
Description: In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (\> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
Study: NCT02524717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
Study: NCT01083810

Intervention type: DRUG
Intervention: Lopinavir/Ritonavir (Kaletra)
Description: 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra

Intervention type: DRUG
Intervention: Lopinavir/Ritonavir (Kaletra)
Description: 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra

Intervention type: DRUG
Intervention: Lopinavir/Ritonavir (Kaletra)
Description: 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
Study: NCT03880435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalobarrier® gel endo
Description: Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
Study: NCT02257294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
Study: NCT01969448

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inframammary Fold Incision or Lateral Radial Incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Radial Incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inframammary Fold Incision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser-assisted fluorescence angiography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser-assisted fluorescence angiography

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser-assisted fluorescence angiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Study: NCT03994393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance.
Study: NCT00648141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule twice daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 75 mg oral capsule twice daily for 12 weeks
Study: NCT02877849

Intervention type: DEVICE
Intervention: MRI: Brain Imaging data collection
Description: This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.

Intervention type: DEVICE
Intervention: MRI: Brain Imaging data collection
Description: This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
Study: NCT03768895

Intervention type: RADIATION
Intervention: MRI
Description: The technique used was coronal and axial T1 and T2\*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2\*WI.
Study: NCT02293993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Study: NCT00979017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin, by intravenous infusion, 10 mg/kg every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide at 200 mg/m2 daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
Study: NCT02362542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
Study: NCT01725256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001 (sodium nitrite inhalation solution)
Description: Dose arms specify dose loaded into the I-neb AAD System nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001 (sodium nitrite inhalation solution)
Description: Dose arms specify dose loaded into the I-neb AAD System nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001 (sodium nitrite inhalation solution)
Description: Dose arms specify dose loaded into the I-neb AAD System nebulizer
Study: NCT00120289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release niacin
Description: 2,000 mg/day or 1,500 mg/day if higher dose not tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
Study: NCT01001858

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis and monitoring of OSA patients
Description: The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis and monitoring of OSA patients
Description: The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis and monitoring of OSA patients
Description: The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
Study: NCT02521909

Intervention type: DEVICE
Intervention: ProMark (Tooth Extraction for Assessment of Different Apex Locators)
Description: The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.

Intervention type: DEVICE
Intervention: Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)
Description: The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.

Intervention type: DEVICE
Intervention: NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)
Description: The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
Study: NCT01927393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: palliative care
Description: Receive PCPI

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive education sessions
Study: NCT03037125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Split Crest with PRF
Description: Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Split Crest without PRF
Description: Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
Study: NCT01927393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT01969448

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Study: NCT03375294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
Study: NCT02182869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivent® HFA inhalation aerosol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combivent® CFC inhalation aerosol
Study: NCT01927393

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephone-based intervention
Description: Receive telephone contacts
Study: NCT03945734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Helping
Description: Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.